Abstract
The novel agent VT-1161 is safe and as effective as fluconazole for treating acute vulvovaginal candidiasis infections. Furthermore, it is more effective than fluconazole for preventing recurrent vulvovaginal candidiasis infections, particularly at its mid- and high doses, according to results from a phase 2 dose-ranging study. VT-1161 is now being evaluated in patients with recurrent vulvovaginal candidiasis in the REVIVE trial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
